Connect your AI

Biohaven BHVN Research and development accrual

Other financials

Income statement

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Returns & leverage

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:UpfrontPaymentsCashPaymentsResearchAndDevelopmentAccrual.

The official record: Biohaven’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's research and development accrual.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biohaven's research and development accrual?: Biohaven (BHVN) reported research and development accrual of $1.25M in Q3 2025.